Dr. Jad Kebbe, a pulmonologist at the University of Oklahoma Health Sciences Center, discusses the risks of inhaling wildfire ...

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its ...

The study in the European Respiratory Journal used advanced spatial mapping techniques to compare healthy lung tissues and ...

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage ...

Key findings • Sarcoidosis patients are prone to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, increased severity, morbidity and greater mortality of coronavirus disease 2019 ...

The DWP's PIP benefits are still available despite potential changes and could get you £812 a month if you have one of these ...

In a new report out last week based in part on pollen scores, Tulsa ranked fourth among the most allergy-affected cities ...

A new medical review published in the Journal of Occupational Medicine and Toxicology has uncovered a troubling rise in ...

Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of ...

Gastroesophageal reflux disease (GERD) is associated with more severe interstitial lung disease (ILD) in systemic sclerosis (SSc), according to study findings published in Rheumatology.

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

Q4 2024 Earnings Call Transcript March 13, 2025 aTyr Pharma, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. Operator: Good afternoon, ladies and gentlemen, and ...